ReviewBlood reviews2012
The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.
Review in Blood reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 123 citations in OpenAlex.
- A TMPRSS6-inhibiting mAb improves disease in a β-thalassemia mouse model and reduces iron in healthy humans.JCI insight · 2025Trial
- Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassaemia: An open-label phase 2 study.British journal of haematology · 2025Trial
- Splenectomy improves anaemia but does not reduce iron burden in patients with haemoglobin H Constant Spring disease.Blood transfusion = Trasfusione del sangue · 2014Trial
- Delayed recognition and significant morbidity in adults with non-transfusion-dependent thalassemia.Blood advances · 2026Article
- MiR-223-3p regulates erythropoiesis by targeting TGFBR3/Smad signaling pathway in hemoglobin H-Constant Spring disease.Annals of medicine · 2025Article
- Leptin and thyroid hormones in beta-thalassemia major: A cross-sectional study.Caspian journal of internal medicine · 2025Article
- Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.American journal of hematology · 2024Article
- Global Trends on β-Thalassemia Research Over 10 Years: A Bibliometric Analysis.International journal of general medicine · 2024Article
- Article
- A randomized placebo-controlled clinical trial of oral green tea epigallocatechin 3-gallate on erythropoiesis and oxidative stress in transfusion-dependent β-thalassemia patients.Frontiers in molecular biosciences · 2023Article
- Non-Transfusion-Dependent Thalassemia: A Panoramic Review.Medicina (Kaunas, Lithuania) · 2022Review
- Effects of green tea extract treatment on erythropoiesis and iron parameters in iron-overloaded β-thalassemic mice.Frontiers in physiology · 2022Article
- JAK2V617F mutation in patients with β-thalassemia disease: prevalence and clinical characteristics.Annals of hematology · 2021Article
- The transfusion management of beta thalassemia in the United States.Transfusion · 2021Review
- The Role of Iron in Benign and Malignant Hematopoiesis.Antioxidants & redox signaling · 2021Review
- The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.International journal of molecular sciences · 2021Article
- Rare Presentation of Right Adrenal Mass: Extramedullary Haematopoiesis in a Patient with Thalassaemia Intermedia.Journal of the ASEAN Federation of Endocrine Societies · 2021Article
- Correlation of Serum Ferritin and Liver Iron Concentration with Transient Liver Elastography in Adult Thalassemia Intermedia Patients with Blood Transfusion.Journal of blood medicine · 2021Article
- The relation between mitogen activated protein kinase (MAPK) pathway and different genes expression in patients with beta Thalassemia.Biochemistry and biophysics reports · 2020Article
- The mechanisms of pathological extramedullary hematopoiesis in diseases.Cellular and molecular life sciences : CMLS · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Ineffective erythropoiesis is the hallmark of beta-thalassemia that triggers a cascade of compensatory mechanisms resulting in clinical sequelae such as erythroid marrow expansion, extramedullary hematopoiesis, splenomegaly, and increased gastrointestinal iron absorption. Recent studies have begun to shed light on the complex molecular mechanisms underlying ineffective erythropoiesis and the associated compensatory pathways; this new understanding may lead to the development of novel therapies. Increased or excessive activation of the Jak2/STAT5 pathway promotes unnecessary disproportionate proliferation of erythroid progenitors, while other factors suppress serum hepcidin levels leading to dysregulation of iron metabolism. Preclinical studies suggest that Jak inhibitors, hepcidin agonists, and exogenous transferrin may help to restore normal erythropoiesis and iron metabolism and reduce splenomegaly; however, further research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.